טוען...
Docetaxel-based chemotherapy as second-line regimen for advanced thymic carcinoma
Thymic carcinoma is an uncommon neoplasm. The efficacy of second-line treatment with docetaxel in advanced thymic carcinoma has not been well studied. Therefore, we conducted a review of the efficacy of docetaxel-based chemotherapy as a second-line regimen for advanced thymic carcinoma. Fifteen pati...
שמור ב:
| הוצא לאור ב: | Thorac Cancer |
|---|---|
| Main Authors: | , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
BlackWell Publishing Ltd
2014
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4704314/ https://ncbi.nlm.nih.gov/pubmed/26766995 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.12064 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|